Complex PCI
Resolute Onyx Drug-Eluting Stent
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Resolute Onyx Drug-Eluting Stent
Resolute Onyx™ DES offers flexibility, conformability, deliverability, and enhanced visibility1 for complex percutaneous coronary intervention (PCI), including:
High bleeding risk patients
Chronic total occlusion
Small vessels (2.0 mm)
Extra-large vessels (4.5–5.0 mm)
Diabetic patients
Resolute Onyx is the only DES proven safe and effective in high bleeding risk (HBR) patients with 1-month DAPT labeling, based on results from the Onyx ONE Clear Analysis.2
Single-wire Design — increasing conformability and apposition3
BioLinx Polymer — offering superior thromboresistance4
The Onyx ONE Month DAPT Program
Resolute Onyx DES offers exceptional deliverability and enhanced visibility1 for complex chronic total occlusion (CTO) cases.
When it comes to treating small vessels, Resolute Onyx DES offers the lowest crossing profile for superior deliverability1‡ and is engineered to expand from 2.0 mm to 3.25 mm.1§
Lower Is Better
Average Force (gF)
Our smallest DES expands from 2.0–3.25 mm
and features low foreshortening when
expanded to 3.25 mm.1§
3.25 mm
Post-dilatation limit for 2.0 mm sizes.
As the first DES with 4.5 and 5.0 mm sizes, Resolute Onyx DES expands treatment options for patients with extra-large vessels. It sustains structural strength and coating integrity when overexpanded and its 5 Fr compatibility is designed with the transradial approach in mind.
Resolute Onyx DES
5.0 mm x 18 mm DES
1.62 mm maximum distance between stent struts
Synergy DES
4.0 mm x 20 mm DES
1.87 mm maximum distance between stent struts
Deployed to 5.75 mm (maximum labeled overexpansion)1§
Higher Is Better
In recent Medtronic studies, diabetes patients make up over 35% of the coronary stents implanted.5-6
Log in to Medtronic Academy to browse a variety of Coronary education, training, and resources.
Log in to Medtronic AcademyResolute
Onyx DES
Resolute Onyx DES is designed to be placed inside a diseased coronary artery to keep the artery open so that blood can access the heart.
View Resolute Onyx DESView our latest product and therapy innovations, clinical evidence, and educational offerings for the interventional cardiology space.
View the latest from MedtronicMedtronic and Medtronic logo are trademarks of Medtronic. Third-party trademarks ("™*") belong to their respective owners. All other brands are trademarks of a Medtronic entity.
Endpoints presented from the PERSPECTIVE Study (NCT02884206) were not powered.
Testing performed on smallest diameters available for Abbott Xience Alpine™*, Biotronik Orsiro™*, Boston Scientific Promus Premier™*, Boston Scientific Synergy™*, Medtronic Resolute Integrity™, and Medtronic Resolute Onyx coronary stents.
The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Post-dilatation required for overexpansion.
Based on bench test data on file at Medtronic. May not be indicative of clinical performance.
Resolute Onyx DES, Instructions for Use.
Shown in independent assessment. Data on file at Medtronic.
Finn, et al. Assessment of acute thrombogenicity and albumin bindings in the Resolute Onyx Zotarolimus-eluting Coronary Stent System. Data presented at PCR 2019.
Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med. March 26, 2020;382(13):1208-1218.
Kirtane A, et al. One Month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results of Onyx ONE Clear. Presented online at ACC 2020.